NCT07109297View on ClinicalTrials.gov

Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in India

PHASE4RecruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2026

Conditions
RSV Immunization
Interventions
BIOLOGICAL

Nirsevimab

Pharmaceutical form:Sterile solution for injection-Route of administration:Intramuscular

Trial Locations (3)

411007

RECRUITING

Investigational Site Number : 3560004, Pune

700017

RECRUITING

Investigational Site Number : 3560003, Kolkata

441108,

RECRUITING

Investigational Site Number : 3560007, Nagpur

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT07109297 - Study of Monoclonal Antibody Nirsevimab Against Respiratory Syncytial Virus (RSV) in Participants up to 24 Months of Age in India | Biotech Hunter | Biotech Hunter